The medical marijuana markets in Germany and the Netherlands were valued at approximately USD 76.9 million in 2024 and are projected to experience a robust compound annual growth rate (CAGR) of 25.3% from 2025 to 2030. This substantial growth can be largely attributed to the increasing acceptance of cannabis for therapeutic applications, alongside progressive changes in regulatory frameworks governing its use. Notably, the removal of cannabis from the Narcotics List has significantly simplified the prescription process, enabling doctors to more readily prescribe medical marijuana. This regulatory shift has led to a dramatic rise in the number of patients opting for cannabis-based therapies, thereby fueling the market’s expansion in both countries.

Medical marijuana, often referred to as medical cannabis, has a long-standing history of therapeutic use that spans centuries. Despite its historical usage, its full potential has been constrained by strict governmental controls and challenges related to production. These restrictions have limited the scope of extensive clinical research on the safety and effectiveness of cannabis-based treatments. Nonetheless, demand for medical cannabis is anticipated to increase as its medicinal benefits become more widely recognized, especially in managing chronic illnesses and alleviating symptoms such as pain and nausea.

A key component driving interest is cannabidiol (CBD), a non-psychoactive substance derived from cannabis, which is gaining prominence due to its therapeutic properties without causing the "high" associated with THC. The surge in clinical trials and research initiatives focused on cannabis is expected to deepen the understanding of its benefits, improve regulatory acceptance, and ultimately stimulate further market growth.

Moreover, the legalization of cannabis for medical use across various countries is playing a significant role in enhancing its popularity as an alternative treatment option. As public and professional awareness about its health benefits continues to grow, the medical marijuana market is positioned for considerable expansion. This growth will likely be supported by the development of innovative therapeutic products designed to meet the increasing demand from patients seeking alternative and effective treatment options.

Key Market Trends & Insights:

• When analyzing the medical marijuana market by country, The Netherlands emerged as the dominant player, capturing the largest revenue share of 91.2% in 2024. This substantial share highlights the country's well-established regulatory framework, advanced healthcare infrastructure, and widespread acceptance of medical cannabis, which together contribute to its leadership position within the market.

• In terms of product types, oil-based medical marijuana products led the market, accounting for the largest revenue share of 55.3% in 2024. This preference for oil formulations can be attributed to their ease of use, precise dosing capabilities, and versatility in treating various medical conditions. Oil products have gained popularity among patients and healthcare providers alike for these reasons, solidifying their dominant position in the product segment.

• Looking at the market by application, chronic pain management emerged as the leading use case, commanding the largest revenue share in 2024. The effectiveness of medical marijuana in alleviating chronic pain symptoms has made it a preferred treatment option for many patients suffering from long-term pain conditions, driving demand within this application segment.

Order a free sample PDF of the Germany And Netherlands Medical Marijuana Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 76.9 Billion

• 2030 Projected Market Size: USD 299.4 Million

• CAGR (2025-2030): 25.3%

Key Companies & Market Share Insights:

Several key companies dominate the medical marijuana market, including Aphria, Inc., Aurora Cannabis, Tilray, and others. These companies implement a variety of strategic approaches to strengthen their competitive positions and broaden their market presence. Among these strategies are forming strategic collaborations with other industry players and launching new products to meet evolving consumer demands. Additionally, many companies are actively pursuing mergers and acquisitions, which allow them to consolidate resources, share expertise, and efficiently expand their product portfolios as well as their geographic reach within the market.

One notable player, GW Pharmaceuticals, plc, specializes in the medical segment of the cannabis industry. The company manufactures innovative therapeutic products such as Epidiolex, an FDA-approved oral solution specifically designed for treating seizures linked to certain epilepsy syndromes. Another key product is Sativex, a plant-derived cannabinoid prescription medication used to alleviate spasticity symptoms in patients with multiple sclerosis. GW Pharmaceuticals places a strong emphasis on research and clinical trials, leveraging extensive scientific studies to develop effective and innovative treatments for patients suffering from serious medical conditions.

Another prominent company, Organigram Holdings, Inc., offers a broad portfolio of cannabis products including dried flowers, oils, and pre-rolls, which cater to both medical and recreational users. The company is dedicated to quality and innovation in the cannabis industry, focusing on developing premium strains and products tailored to meet the specific needs of patients and consumers. Within the medical marijuana segment, Organigram continues to expand its offerings while maintaining a commitment to high standards and patient-centric solutions.

Key Players

• ADREXpharma GmbH

• Canopy Growth Corporation

• Aphria, Inc

• Aurora Cannabis

• Tilray

• GW Pharmaceuticals, plc

• Organigram Holdings, Inc

• The Cronos Group

• Demecan GmbH

• Cannamedical Pharma GmbH

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The medical marijuana market in Germany and the Netherlands is rapidly growing, driven by increasing acceptance of cannabis for therapeutic use and evolving regulations. Removal of cannabis from restrictive lists has made prescriptions easier, boosting patient numbers. Rising prevalence of chronic diseases and demand for alternative treatments further support market expansion. Ongoing research and legalization efforts are expected to continue fueling growth and innovation in this sector.